Remogliflozin etabonate
- Generic Name
- Remogliflozin etabonate
- Drug Type
- Small Molecule
- Chemical Formula
- C26H38N2O9
- CAS Number
- 442201-24-3
- Unique Ingredient Identifier
- TR0QT6QSUL
- Background
Remogliflozin etabonate has been used in trials studying the treatment and basic science of Type 2 Diabetes Mellitus and Diabetes Mellitus, Type 2.
A First-time-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of GSK189075A in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus
- First Posted Date
- 2012-04-05
- Last Posted Date
- 2012-04-05
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 16
- Registration Number
- NCT01571661
A Study to Assess the Safety of Repeated Doses of GSK189075 and WELLBUTRIN SR in Healthy Male Subjects
Phase 1
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2008-02-28
- Last Posted Date
- 2017-08-24
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 27
- Registration Number
- NCT00625859
- Locations
- ๐บ๐ธ
GSK Investigational Site, Buffalo, New York, United States
A Study to Assess the Safety of Single Doses of GSK189075 in Subjects With Type 1 Diabetes Mellitus
- First Posted Date
- 2007-12-18
- Last Posted Date
- 2017-10-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 10
- Registration Number
- NCT00575159
- Locations
- ๐บ๐ธ
GSK Investigational Site, San Diego, California, United States
A Study to Compare the Effect on Heart Rhythm of 3 Days of GSK189075, Placebo, or Moxifloxacin in Healthy Adults
Phase 1
Completed
- Conditions
- Type 2 Diabetes MellitusDiabetes Mellitus, Type 2
- First Posted Date
- 2007-09-20
- Last Posted Date
- 2012-03-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 78
- Registration Number
- NCT00532610
- Locations
- ๐บ๐ธ
GSK Investigational Site, Madison, Wisconsin, United States
A Study To Assess The Safety And Tolerability Of GSK189075 When Given With A Total Daily Dose Of >/ 2000mg of Metformin
Phase 1
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2007-08-22
- Last Posted Date
- 2017-09-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 50
- Registration Number
- NCT00519480
- Locations
- ๐ฉ๐ช
GSK Investigational Site, Berlin, Germany
A Study of the Effects of GSK189075 on PK Profiles of an Oral Contraceptive Pill When Given to Healthy Female Volunteers
Phase 1
Completed
- Conditions
- Type 2 Diabetes MellitusDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2007-07-20
- Last Posted Date
- 2012-06-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 22
- Registration Number
- NCT00504816
- Locations
- ๐บ๐ธ
GSK Investigational Site, Miramar, Florida, United States
A Study of the Effects of Ketoconazole Taken Orally Has on the PK Profiles of a Dose of GSK189075 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Diabetes Mellitus, Type 2Type 2 Diabetes Mellitus
- First Posted Date
- 2007-07-16
- Last Posted Date
- 2012-06-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 22
- Registration Number
- NCT00501397
- Locations
- ๐บ๐ธ
GSK Investigational Site, Columbus, Ohio, United States
A Study to Evaluate and Study Drug Levels in Blood Plasma When Giving High Doses of GSK189075 to Healthy Volunteers
Phase 1
Completed
- Conditions
- Type 2 Diabetes MellitusDiabetes Mellitus, Type 2
- First Posted Date
- 2007-07-16
- Last Posted Date
- 2012-06-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 12
- Registration Number
- NCT00501930
- Locations
- ๐บ๐ธ
GSK Investigational Site, Madison, Wisconsin, United States
A Comparison Of Study Drug Blood Levels After One Dose Of GSK189075 In Subjects With Normal And Reduced Kidney Function
Phase 1
Completed
- Conditions
- Type 2 Diabetes MellitusDiabetes Mellitus, Type 2Renal Insufficiency
- Interventions
- First Posted Date
- 2007-07-16
- Last Posted Date
- 2012-03-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 29
- Registration Number
- NCT00501462
- Locations
- ๐บ๐ธ
GSK Investigational Site, Austin, Texas, United States
Dose-Ranging Study in Treatment Naive Type 2 Diabetes Mellitus(T2DM)
Phase 2
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2007-07-12
- Last Posted Date
- 2017-12-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 334
- Registration Number
- NCT00500331
- Locations
- ๐ฟ๐ฆ
GSK Investigational Site, Roodepoort, South Africa
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
ยฉ Copyright 2025. All Rights Reserved by MedPath